Immuneering (IMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on the stock and has a $9.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ami Fadia has given his Buy rating due to a combination of factors that highlight Immuneering’s promising clinical developments. The recent Phase 2a data for the combination of atebimetinib and mGnP in first-line PDAC patients showed an objective response rate of 39% among 36 patients, along with impressive six-month overall survival and progression-free survival rates of 94% and 72%, respectively. These results suggest a strong efficacy and safety profile for the combination therapy compared to the standard GnP treatment alone.
Ami Fadia’s confidence in Immuneering’s stock is further bolstered by the company’s plans to initiate a pivotal trial for the atebimetinib and mGnP combination in 2026, following regulatory feedback expected in the fourth quarter of 2025. The anticipation of additional Phase 2a data in late 2025 also supports the potential for continued positive outcomes. These factors collectively contribute to a favorable outlook for Immuneering, justifying the Buy rating.
According to TipRanks, Fadia is a 3-star analyst with an average return of 2.0% and a 45.18% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Jazz Pharmaceuticals, and Blueprint Medicines.
In another report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $8.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue